Vertex Pharmaceuticals Reports Positive Phase 3 RAINIER Results for Povetacicept in IgA Nephropathy Published in NEJM Vertex Pharmaceuticals Incorporated has announced the publication of Phase 3 RAINIER trial results for…
Ionis and Roche Report Phase 3 Sefaxersen Data Showing Significant Proteinuria Reduction in IgA Nephropathy Ionis Pharmaceuticals, Inc. and its partner Roche have announced positive late-breaking results from the ongoing…
Genmab Reports Positive Phase 3 RAINFOL-02 Results for Rina-S in Platinum-Resistant Ovarian Cancer Genmab A/S has announced positive topline results from the global Phase 3 RAINFOL™-02 clinical trial evaluating rinatabart…
TG Therapeutics Reports Initial Clinical Results for Azer-Cel CAR T-Cell Therapy in Progressive Multiple Sclerosis TG Therapeutics, Inc. has announced initial clinical results from its ongoing Phase 1 study evaluating…
Bristol Myers Squibb Reports Early Safety and Efficacy Results for Investigational CAR T-Cell Therapy Zola-Cel in Multiple Sclerosis Bristol Myers Squibb has announced interim safety and efficacy findings from the…
BeOne Medicines Reports Longer-Term Survival Benefits for TEVIMBRA-Based Regimens in HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd., a global oncology company, has announced new long-term survival results from the planned second…
Convergent Therapeutics Reports 84% PSA50 Response Rate for CONV01-α in Phase 2 Prostate Cancer Study Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for cancer treatment, has announced…
LivaNova Reports 36-Month CORE-VNS Study Results Showing Sustained Seizure Reduction and Improved Quality of Life in Drug-Resistant Epilepsy LivaNova PLC, a medical technology company specializing in therapies for neurological and…
Brenus Pharma Reports Promising Phase Ia Results for STC-1010 in Metastatic Colorectal Cancer, With 57% Objective Response Rate Brenus Pharma, a clinical-stage biotechnology company developing innovative immunotherapies for cancer, has…
Salubris Biotherapeutics Presents Updated Phase 1b/2 Data for 5T4-Targeted ADC JK06 in Advanced Solid Tumors at ESMO 2026 Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing…
Mundipharma Reports Additional Phase III ReSPECT Results Supporting REZZAYO for Invasive Fungal Disease Prevention After Stem Cell Transplantation Mundipharma has announced additional findings from the global Phase III ReSPECT clinical…
Zai Lab Secures $250 Million PIPE Financing to Support Global Development of Zocilurtatug Pelitecan Zai Lab Limited, an innovation-driven global biopharmaceutical company, has entered into a securities purchase agreement to…